• Overview
  • Eligibility
  • More info
  • Locations

Resynchronization for Ambulatory Heart Failure Trial - LV Endocardial (NCT02757976)

Medtronic
This trial will compare two strategies for patients with Heart Failure, Left Ventricular systolic dysfunction, and intermediate QRS durations. The control group is conventional CRT. The experimental group is LVendo CRT
  • Device: Conventional CRT
    Patients randomized to the Conventional CRT will receive a CRT device with or without ICD. Device implantation will be performed within 10 working days of randomization. Conscious sedation or general anesthesia can be used for the implant procedure. The device will be implanted in a facility that has the capacity to perform coronary sinus venography at the time of implantation. The RA lead will be placed in the RA appendage or high RA. The RV lead should be placed at the RV apex or distal RV septum (R wave > 7 mV, pacing threshold < 1.5 V at a pulse-width of 0.5 ms). The LV lead should be positioned through the CS to an LV branch. The lead should be placed at one of the left ventricular venous branches, avoiding the LV apex and scar region identified by pre-implant imaging.
    • Device: LV endocardial CRT
      Patients randomized to LV endocardial CRT will receive a CRT device with or without ICD, placed in the same time frame, and will have RA and RV leads implanted as the conventional CRT group. The device will be implanted in a facility that has the capacity to perform trans-atrial septal puncture with ultrasound guidance (TEE or ICE) at the time of implantation. The LV lead will be placed using a trans-atrial septal approach, using a specially designed puncture tools and LVendo delivery tool kits specifically designed for this study. Special care will be taken to avoid the LV apex and transmural scar identified by pre-implant imaging.
      Ages eligible for Study
      18 Years and older
      Genders eligible for Study
      All
      Accepts Healthy Volunteers
      No
      Inclusion Criteria:
      • Patients with NYHA Class II or III or ambulatory IV HF symptoms
      • Optimal HF Medical Therapy of at least 3 months (2009 ACCF/AHA, ESC 2012)
      • LVEF less than or equal to 35%
      • Sinus rhythm (can have paroxysmal atrial fibrillation)
      • QRS morphology is non-RBBB
      • QRS durations more than or equal to 120 ms, but less than 150 ms
      • Patients are able to receive chronic oral anticoagulation
      • Patients with pacemaker or ICD that meet the above criteria may be upgraded to CRT-D or CRT-P
      Exclusion Criteria:
      • Planned Atrial Fibrillation Ablation within 12 months
      • Patients with mitral or tricuspid prosthetic valve that precludes the placement of an LV lead transvenously or trans-septally
      • Patients with RBBB
      • Patients with LV thrombus
      • Patients with permanent atrial fibrillation
      • Patients with contraindications to oral anti-coagulation
      • In-hospital patients with acute cardiac or non-cardiac illness that requires intensive care
      • Acute coronary syndrome (including MI) < 4 weeks
      • Coronary revascularization (CABG or PCI) < 3 months
      • Uncorrected or uncorrectable primary valvular disease
      • Restrictive, hypertrophic or reversible form of cardiomyopathy
      • Severe primary pulmonary disease such as cor pulmonale
      • Expected to undergo cardiac transplantation within one year (status I)
      • Patients with a life expectancy of less than one year from non-cardiac cause.
      • Patients included in other clinical trials that will affect the objectives of this study
      • Those unable or unwilling to provide informed consent
      • Those with a history of noncompliance to medical therapy
      Patients randomized to the Conventional CRT will receive a CRT device with or without ICD. Device implantation will be performed within 10 working days of randomization.

      Patients randomized to LV endocardial CRT will receive a CRT device with or without ICD, placed in the same time frame and will have RA and RV leads implanted as the conventional CRT group. The device will be implanted in a facility that has the capacity to perform trans-atrial septal puncture with ultrasound guidance. The LV lead will be placed using a trans-atrial septal approach using a specially designed puncture tools and LVendo delivery tool kits specifically designed for this study

      11 locations

      Canada (11)
      • Libin Cardiovascular Institute
        not yet recruiting
        Calgary, Alberta, Canada
      • Royal Columbia Hospital
        not yet recruiting
        New Westminster, British Columbia, Canada
      • Vancouver General Hospital
        not yet recruiting
        Vancouver, British Columbia, Canada, K4A 3B2
      • Queen Elizabeth II Health Science
        not yet recruiting
        Halifax, Nova Scotia, Canada
      • London Health Science Centre
        not yet recruiting
        London, Ontario, Canada
      • University of Ottawa Heart Institute
        not yet recruiting
        Ottawa, Ontario, Canada
      • St. Michael Hospital
        not yet recruiting
        Toronto, Ontario, Canada
      • McGill University Health Centre
        not yet recruiting
        Montréal, Quebec, Canada
      • Montreal Heart Institute
        not yet recruiting
        Montréal, Quebec, Canada
      • Institut Univ.cardiologie/pneumologie de Québec
        not yet recruiting
        Quebec City, Quebec, Canada
      • CHUS Le Centre hospitalier universitaire de Sherbrooke
        not yet recruiting
        Sherbrooke, Quebec, Canada
      Status:
      not yet recruiting
      Type:
      Interventional
      Phase:
      -
      Start:
      31 December, 2017
      Updated:
      06 December, 2017
      Participants:
      350
      A girl giving information about available additional trials.

      FindMeCure helps you find, understand and join clinical trials from all over the world.

      There are more clinical trials for your condition!